Prakt. lékáren. 2019; 15(1): 12-18 [Interní Med. 2018; 20(5): 227-232]

Pharmacotherapy of the symptoms of chronic venous disease

Jana Hirmerová
II. interní klinika LF UK a FN Plzeň

The main pathogenetic mechanisms of chronic venous disease are increased venous pressure and impaired venous outflow. Objective signs of the disorder include varices, oedema, skin changes and, in the most advanced stage, leg ulcer. Subjective symptoms are represented by various complaints about discomfort in the legs, typically worsening after long standing or sitting, in hot weather or in the evening. The treatment should be complex and consists of regime measures and physiotherapy, compression therapy, surgical and endovascular methods, and pharmacotherapy. In this indication, medicinal products from a heterogeneous group of venoactive drugs are being used. They are mainly of plant origin (flavonoids, saponins and other), some of them also semi-synthetic or synthetic (calcium dobesilate). Venoactive drugs act by increasing venous tone, improving capillary permeability, enhancing lymphatic drainage, they exert haemorheologic and antiinflammatory effects as well. The guidelines for their use are based on the results of meta-analyses, systematic reviews and consensus statements. Most convincing data are available for the efficacy and safety of micronized purified flavonoid fraction. In the stage of venous ulcer, sulodexid and pentoxiphyllin has proven benefit as well. Venoactive drugs are recommended for the management of symptomatic chronic venous disease in all stages.

Keywords: chronic venous disease, venoactive drugs, guidelines

Published: March 15, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hirmerová J. Pharmacotherapy of the symptoms of chronic venous disease. Praktické lékárenství. 2019;15(1):12-18.
Download citation

References

  1. Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. 2014; 130(4): 333-346. Go to original source...
  2. Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011; 41(1): 117-125. Go to original source... Go to PubMed...
  3. Raffetto JD, Mannello F. Pathophysiology of chronic venous disease. Int Angiol. 2014; 33(3): 212-221. Go to PubMed...
  4. Roztočil K. Chronická žilní onemocnění. In: Roztočil K, Piťha J a kol. Nemoci končetinových cév. Mladá fronta, a. s. 2017: 280-306.
  5. Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maesenner M, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018; 37(3): 181-254. Go to original source... Go to PubMed...
  6. Raju S, Neglén P. Clinical practice. Chronic venous insufficiency and varicose veins. N Engl J Med. 2009; 360(22): 2319-2327. Go to original source... Go to PubMed...
  7. Nicolaides A, Kakkos S, Eklof B, Perrin M, Nelzen O, Neglen P et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33: 87-208. Go to PubMed...
  8. Roztočil K. Léčba žilních onemocnění. In: Karetová D, Chochola M a kol. Vaskulární medicína. Maxdorf 2017:117-119.
  9. Hoppensteadt DA, Fareed J. Pharmacological profile of sulodexide. Int Angiol. 2014; 33(3): 229-235. Go to PubMed...
  10. Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev. 2012; 12: CD001733. Go to original source... Go to PubMed...
  11. Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capell? D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005(3): CD003229.
  12. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4: CD003229. Go to original source... Go to PubMed...
  13. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev. 2012; 11: CD003230. Go to original source... Go to PubMed...
  14. Jantet G. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids. Angiology. 2000; 51(1): 31-37. Go to original source... Go to PubMed...
  15. Rabe E, Jaeger KA, Bulitta M, Pannier F. Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology. 2011; 26(4): 162-168. Go to original source...
  16. Rabe E, Stücker M, Esperester A, Schäfer E, Ottillinger B. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency - results of a double-blind placebo-controlled study. Eur J Vasc Endovasc Surg. 2011;41(4): 540-547. Go to original source... Go to PubMed...
  17. Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol. 2012; 31(4): 310-315. Go to PubMed...
  18. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg. 2005; 30(2): 198-208. Go to original source... Go to PubMed...
  19. Scallon C, Bell-Syer SE, Aziz Z. Flavonoids for treating venous leg ulcers. Cochrane Database Syst Rev. 2013(5): CD006477. Go to original source...
  20. Nelson EA, Prescott RJ, Harper DR, Gibson B, Brown D, Ruckley CV. A factorial, randomized trial of pentoxifylline or placebo, four-layer or single-layer compression, and knitted viscose or hydrocolloid dressings for venous ulcers. J Vasc Surg. 2007; 45(1): 134-41. Go to original source... Go to PubMed...
  21. Wu B, Lu J, Yang M, Xu T. Sulodexide for treating venous leg ulcers. Cochrane Database Syst Rev. 2016(6): CD010694. Go to original source...
  22. O'Donnell TF, Passman MA, Marston WA, Ennis WJ, Dalsing M, Kistner RL et al. Management of venous leg ulcers: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2014; 60: 3S-59S. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.